2018 American Transplant Congress
Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
Cannabidiol (CBD), a major purified non-psychoactive component of marijuana with anticonvulsant properties, is being studied under an expanded access IND as an adjuvant treatment for…2018 American Transplant Congress
The Effect of Tacrolimus Trough Level and Intrapatient Variability on the Transplant Outcomes in Kidney Transplantation
Background: Tacrolimus (TAC) is the mainstay of immunosuppression for kidney transplantation (KT). Although TAC has a narrow therapeutic index, appropriate trough concentrations of TAC have…2018 American Transplant Congress
Once Daily CNI Administration Based on Pharmacodynamic Analysis for Preventing Viral Infection
BackgroundInfectious complications under immunosuppressive therapy are inevitable problems. Viral infection (include reactivation) occurs at a certain frequency even if immunosuppressive agents are totally adjusted by…2018 American Transplant Congress
Presence of Chronic Vascular Lesions on Allograft Biopsy is Associated with Greater Improvement in Renal Function after Conversion from Tacrolimus to Belatacept
Background: Conversion from tacrolimus to belatacept has been shown to be beneficial for an increasing number of kidney transplant (KT) patients. However, predicting factors for…2018 American Transplant Congress
Long Term Outcomes of a Steroid Free, Low Dose Tacrolimus with Everolimus Regimen in Kidney Transplant
Tacrolimus (Tac) is the most effective immunosuppressive agent to prevent acute allograft rejection. However, long-term transplant (Tx) outcomes are limited, at least in part, by…2018 American Transplant Congress
Superiority of Early Everolimus-Based Quadruple Immunosuppression versus Standard Triple Therapy after Lung Transplantation: 12 Months Results from Prospective 4EVERLUNG Study in Germany
The 4Everlung trial was designed to evaluate the benefit of early everolimus (EVR)-based quadruple low immunosuppressive (IS) regimen on kidney function (RF) after LTx.4EVERLUNG is…2018 American Transplant Congress
Effect and Reasons of Rescue Switch to Belatacept among 73 Calcineurin-Inhibitors Treated Kidney Allograft Recipients – A Three Years Retrospective Cohort, Single Center Study
IntroductionAfter kidney transplantation, long-term immunosuppression with calcineurin inhibitors (CNIs) or mTOR inhibitors (mTORi) leads to adverse effects, such as nephrotoxicity and proteinuria. Currently, available data…2018 American Transplant Congress
Clinical Outcomes of Conversion from Calcineurin Inhibitor to Belatacept-Based Immunosuppression in Highly Sensitized Kidney Transplant Recipients
Cedars Sinai Medical Center, Los Angeles.
Introduction:Efficacy of belatacept when converted from calcineurin inhibitors (CNI) in high immunologic risk patients has not been established. We examined the impact of HLA-sensitization on…2018 American Transplant Congress
Calcineurin Inhibitors, Macrolides, and the Risk of Adverse Drug Events in Kidney Transplant Recipients
1Univ of Alberta, Edmonton, Canada; 2Univ of Calgary, Calgary, Canada; 3Saint Louis Univ, St. Louis.
Background: After kidney transplantation, calcineurin inhibitors (CNIs, cyclosporine, tacrolimus) are key components of immunosuppression but have multiple potential drug interactions. Macrolide antibiotics are often used…2018 American Transplant Congress
Impact of Direct Acting Antivirals of Hepatitis C Virus Therapy on Tacrolimus Dosing Post-Liver Transplant
Michigan Medicine, Ann Arbor, MI.
Background: Direct acting antivirals (DAA) have transformed hepatitis C virus (HCV) management post-liver transplant (LT). As HCV clears, hepatic metabolism improves, resulting in decreased tacrolimus…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 16
- Next Page »